You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : COMMERCIAL SERVICES & SUPPLIES
  3. INDUSTRY : MISCELLANEOUS COMMERCIAL SERVICES
  4. GRI BIO INC

GRI Bio Inc XNAS: GRI

GRI Bio Inc Live Share Price Today, Share Analysis and Chart

Download real time

6.70 0.18 (2.76%)

39.09% Fall from 52W High

34,236 XNAS Volume

High volume today

XNAS 19 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
12.7 / 100
Momentum Score
Technically Bullish
72.4 / 100
Analyst Price Target
No estimates available

14

S

5

W

3

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

Not enough data available


GRI Bio Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

GRI Bio Inc Stock Analysis

GRI Bio Inc stock analysis with key metrics, changes, and trends.

GRI Bio Inc MetricVALUECHANGE %TRENDANALYSIS
Stock Price$6.70-31.77%negative

Stock Price fell 31.77% and underperformed its sector by 43.13% in the past year.

Mutual Fund Holding1.48 %0.72%positive

Mutual Fund Holding increased by 0.72% in the last quarter to 1.48.

Institutional Holding2.51 %0.96%positive

Institutional Holding increased by 0.96% in the last quarter to 2.51.



Loading data..

GRI Bio Inc - Company Profile

What does GRI Bio Inc do?

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio Inc Management structure

All Gross Remunerations are in USD
Dr. W. Marc Hertz, PhD
President, Chief Executive Officer and Director
617.22 K
2024
Gross Remuneration
Year
Ms. Leanne M. Kelly
Chief Financial Officer and Principal Accounting Officer
469.42 K
2024
Gross Remuneration
Year
Dr. Vipin Kumar Chaturvedi, PhD
Chief Scientific Officer
419.42 K
2024
Gross Remuneration
Year
Dr. Albert Agro, PhD
Chief Medical Officer
-
2024
Gross Remuneration
Year

GRI Bio Inc Board of directors

All Gross Remunerations are in USD
Mr. David Szekeres
Chairman of the Board
91 K
2024
Gross Remuneration
Year
Ms. Camilla V. Simpson, M.Sc.
Independent Director
64.5 K
2024
Gross Remuneration
Year
Mr. Roelof Rongen
Independent Director
57.5 K
2024
Gross Remuneration
Year
Mr. David Baker
Director
40 K
2024
Gross Remuneration
Year
Dr. W. Marc Hertz, PhD
President, Chief Executive Officer and Director
-
2024
Gross Remuneration
Year

GRI Bio Inc FAQ

How is GRI Bio Inc today?
GRI Bio Inc today is trading in the green, and is up by 2.76% at 6.70.
GRI Bio Inc is currently trading up 2.76% on an intraday basis. In the past week the stock rose 8.94%. stock has been up 793.33% in the past quarter and fell -31.77% in the past year. You can view this in the overview section.